1. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies
- Author
-
Juha Rinne, Francisco R. López-Picón, Elena Rodriguez-Vieitez, Rainer Hinz, Leonardo Iaccarino, Rosa Maria Moresco, Agneta Nordberg, Marie Joao Santiago-Ribeiro, Alexander Gerhard, Gitte M. Knudsen, Karl Herholz, Albert D. Windhorst, Matthias M. Herth, Adriaan A. Lammertsma, Johnny Vercouillie, Sabina Pappatà, Christer Halldin, Oskar Hansson, David J. Brooks, Anthony Gee, Koen Van Laere, Bertrand Kuhnast, Ronald Boellaard, Michel Bottlaender, Federico Turkheimer, Andrea Varrone, Alexandra Winkeler, Sylvie Chalon, Andreas H. Jacobs, Daniela Perani, Michael A. Carroll, Paul Edison, Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, ACS - Heart failure & arrhythmias, Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Chalon, Sylvie, VU University Medical Center [Amsterdam], Univ Groningen, Univ Med Ctr Groningen, Lund University [Lund], Perani, D, Iaccarino, L, Lammertsma, Aa, Windhorst, Ad, Edison, P, Boellaard, R, Hansson, O, Nordberg, A, Jacobs, A, on behalf of all partners of the IMBI, Project, Lammertsma, A, Windhorst, A, Bottlaender, M, Brooks, D, Carroll, M, Chalon, S, Gee, A, Gerhard, A, Halldin, C, Herholz, K, Herth, M, Hinz, R, Knudsen, G, Kuhnast, B, Lopez-Picon, F, Moresco, R, Pappata, S, Rinne, J, Rodriguez-Vieitez, E, Santiago-Ribeiro, M, Turkheimer, F, Van Laere, K, Varrone, A, Vercouillie, J, and Winkeler, A
- Subjects
0301 basic medicine ,18-KDA TRANSLOCATOR PROTEIN ,MILD COGNITIVE IMPAIRMENT ,Epidemiology ,PET TRACER F-18-AV-1451 ,[SDV]Life Sciences [q-bio] ,Diagnostic tools ,Abnormal protein ,AMYOTROPHIC-LATERAL-SCLEROSIS ,chemistry.chemical_compound ,0302 clinical medicine ,Neuroinflammation ,Medicine ,TAU-PET ,ComputingMilieux_MISCELLANEOUS ,IN-VIVO ,medicine.diagnostic_test ,Health Policy ,Amyloid, Neuroinflammation, PET molecular imaging, Protheinopathies, Radiotracers, Tau ,Neurodegenerative Diseases ,Frontotemporal lobar degeneration ,ALZHEIMERS ASSOCIATION WORKGROUPS ,3. Good health ,[SDV] Life Sciences [q-bio] ,Psychiatry and Mental health ,Radiotracers ,Positron emission tomography ,Protheinopathie ,Specific protein ,Amyloid ,PET molecular imaging ,Neuroimaging ,Neuropathology ,CEREBRAL AMYLOID ANGIOPATHY ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Humans ,Proteostasis Deficiencies ,FRONTOTEMPORAL LOBAR DEGENERATION ,Radiotracer ,business.industry ,PITTSBURGH COMPOUND-B ,medicine.disease ,030104 developmental biology ,chemistry ,Positron-Emission Tomography ,Protheinopathies ,Neurology (clinical) ,Geriatrics and Gerontology ,Molecular imaging ,Tau ,business ,Pittsburgh compound B ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
- Published
- 2019
- Full Text
- View/download PDF